Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845077 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01845077 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 72 participants.
The verdict
NCT01845077, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.
Interventions
- DRUG 2x500 mg Metformin (Glumetza)
- DRUG 5 mg Linagliptin/1000 mg Metformin FDC
- DRUG 5 mg Linagliptin (Tradjenta)
- DRUG 3x500 mg Metformin (Glumetza)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845077
The ClinicalTrials.gov registry entry for NCT01845077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 2x500 mg Metformin (Glumetza) is the first listed.
NCT01845077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845077 about?
NCT01845077 is a clinical study titled "Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets". The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.
What is the current status of trial NCT01845077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01845077?
The interventions under investigation include: 2x500 mg Metformin (Glumetza) (DRUG), 5 mg Linagliptin/1000 mg Metformin FDC (DRUG), 5 mg Linagliptin (Tradjenta) (DRUG), 3x500 mg Metformin (Glumetza) (DRUG).
Who is sponsoring clinical trial NCT01845077?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.